Vir Biotechnology Inc. (Ticker: VIR) announced on Thursday that its Phase 2 trial, called Peninsula, evaluating VIR-2482 for the prevention of symptomatic influenza ...
MoonLake Immunotherapeutics saw its shares double to $55 in premarket trading following positive trial results. The global Phase 2 trial evaluated the safety ...